These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9013405)

  • 1. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
    Kuhn W; Müller T; Winkel R; Danielczik S; Gerstner A; Häcker R; Mattern C; Przuntek H
    J Neural Transm (Vienna); 1996; 103(10):1187-93. PubMed ID: 9013405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is NADH effective in the treatment of Parkinson's disease?
    Swerdlow RH
    Drugs Aging; 1998 Oct; 13(4):263-8. PubMed ID: 9805207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.
    Birkmayer W; Birkmayer GJ
    Ann Clin Lab Sci; 1989; 19(1):38-43. PubMed ID: 2644889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application.
    Birkmayer JG; Vrecko C; Volc D; Birkmayer W
    Acta Neurol Scand Suppl; 1993; 146():32-5. PubMed ID: 8101414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Putterman DB; Munhall AC; Kozell LB; Belknap JK; Johnson SW
    J Pharmacol Exp Ther; 2007 Oct; 323(1):277-84. PubMed ID: 17660384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH).
    Birkmayer GJ; Birkmayer W
    Acta Neurol Scand Suppl; 1989; 126():183-7. PubMed ID: 2618590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.
    Coban A; Hanagasi HA; Karamursel S; Barlas O
    Br J Neurosurg; 2009 Feb; 23(1):23-9. PubMed ID: 19234905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
    Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment.
    Zhang L; Yuan Y; Tong Q; Jiang S; Xu Q; Ding J; Zhang L; Zhang R; Zhang K
    Int J Neurosci; 2016; 126(7):630-6. PubMed ID: 26004911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.